<DOC>
	<DOC>NCT01189500</DOC>
	<brief_summary>The goal of this study is to evaluate the effect of multiple doses of Desvenlafaxine SR on the pharmacokinetics of Tamoxifen and endoxifen when coadministered to healthy post-menopausal female subjects. This study will also evaluate the safety and tolerability of Desvenlafaxine SR and Tamoxifen when coadministered to healthy post-menopausal female subjects.</brief_summary>
	<brief_title>Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Healthy postmenopausal female subjects, at least 45 years of age, with confirmed postmenopausal status Hysterectomized subjects Body Mass Index (BMI) less than or equal to 34.0 kg/m2 Nonsmoker or smoker of fewer than 5 cigarettes per day as determined by history An informed consent document signed and dated by the subject History of significant blood, kidney, endocrine, lung, gastrointestinal, heart, liver, psychiatric, neurologic, or allergic disease Presence or history of deep vein thrombosis or transient ischemic attack History of seizure disorder Presence or history of glaucoma or increased intraocular pressure Allergy to or unable to tolerate tamoxifen, desvenlafaxine, or venlafaxine History of substance abuse within 1 year of study A positive urine drug screen Treatment with an investigational drug within 30 days Consumption of grapefruit or grapefruit related citrus fruits 12 lead ECG demonstrating QTc &gt;450 msec at screening Pregnant or nursing females Use of prescription or nonprescription drugs and dietary supplements History of sensitivity to heparin or heparin induced thrombocytopenia Severe acute or chronic medical or psychiatric condition or laboratory abnormality Use of CYP 2D6 inhibitors and CYP 3A4 inhibitors/inducers</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Pharmacokinetic</keyword>
	<keyword>safety and tolerability</keyword>
	<keyword>genetic testing</keyword>
	<keyword>CYP 2D6</keyword>
</DOC>